Please wait while the formulary information is being retrieved.
Drug overview for L-GLUTAMINE (glutamine):
Generic name: GLUTAMINE (GLOO-ta-meen)
Drug class:
Therapeutic class: Hematological Agents
L-Glutamine is an amino acid.
No enhanced Uses information available for this drug.
Generic name: GLUTAMINE (GLOO-ta-meen)
Drug class:
Therapeutic class: Hematological Agents
L-Glutamine is an amino acid.
No enhanced Uses information available for this drug.
DRUG IMAGES
L-GLUTAMINE 5 GRAM POWDER PKT
The following indications for L-GLUTAMINE (glutamine) have been approved by the FDA:
Indications:
Sickle cell disease
Professional Synonyms:
Drepanocytic anemia
Hb S disease
Hb-SS disease
Hemoglobin S disease anemia
Hemoglobin SS disease
Sickle cell syndrome
Indications:
Sickle cell disease
Professional Synonyms:
Drepanocytic anemia
Hb S disease
Hb-SS disease
Hemoglobin S disease anemia
Hemoglobin SS disease
Sickle cell syndrome
The following dosing information is available for L-GLUTAMINE (glutamine):
It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
*5 grams to 15 grams orally, twice daily based on body weight.
*Each dose of L-glutamine should be mixed in 8 oz. (240 mL) of cold or room temperature beverage or 4 oz. to 6 oz.
of food before ingestion.
Advise patient to take a missed dose as soon as they remember. Patient should not double the dose that they take.
Instruct patient to mix each dose in 8 oz. (240 mL) of cold or room temperature beverage or 4 to 6 oz. of food.
Advise patient that complete dissolution is not required prior to administration.
AHFS First Release(R). For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.
*5 grams to 15 grams orally, twice daily based on body weight.
*Each dose of L-glutamine should be mixed in 8 oz. (240 mL) of cold or room temperature beverage or 4 oz. to 6 oz.
of food before ingestion.
Advise patient to take a missed dose as soon as they remember. Patient should not double the dose that they take.
Instruct patient to mix each dose in 8 oz. (240 mL) of cold or room temperature beverage or 4 to 6 oz. of food.
Advise patient that complete dissolution is not required prior to administration.
AHFS First Release(R). For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| L-GLUTAMINE 5 GRAM POWDER PKT | Maintenance | Adults take 3 packets (15 gram) mixed in 8 ounces of water, milk or apple juice by oral route 2 times per day |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| L-GLUTAMINE 5 GRAM POWDER PKT | Maintenance | Adults take 3 packets (15 gram) mixed in 8 ounces of water, milk or apple juice by oral route 2 times per day |
The following drug interaction information is available for L-GLUTAMINE (glutamine):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Exagamglogene Autotemcel/Disease Modifying Agents SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The interaction potential of disease modifying agents with exagamglogene autotemcel is unknown.(1) CLINICAL EFFECTS: Disease modifying agents may interfere with exagamglogene autotemcel therapy.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab) at least 8 weeks prior to the start of mobilization.(1) It is recommended that patients be transfused at least 8 weeks prior to the initiation of myeloablative conditioning. At initiation of red blood cell exchange or simple transfusions, discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab).(1) DISCUSSION: There is no experience with the use of disease modifying agents with exagamglogene autotemcel infusion.(1) |
CASGEVY |
| Lovotibeglogene Autotemcel/Disease Modifying Agents SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The interaction potential of disease modifying agents with lovotibeglogene autotemcel is unknown.(1) CLINICAL EFFECTS: Disease modifying agents may interfere with lovotibeglogene autotemcel therapy.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue disease modifying therapies (e.g. voxelotor, crizanlizumab) for sickle cell disease at least 8 weeks prior to start of mobilization and conditioning.(1) DISCUSSION: There is no experience with the use of disease modifying agents with lovotibeglogene autotemcel infusion.(1) |
LYFGENIA |
There are 0 moderate interactions.
The following contraindication information is available for L-GLUTAMINE (glutamine):
Drug contraindication overview.
None.
None.
There are 0 contraindications.
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for L-GLUTAMINE (glutamine):
Adverse reaction overview.
Most common adverse reactions (incidence >10%) are constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.
Most common adverse reactions (incidence >10%) are constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Neuropsychiatric disorder |
There are 12 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Constipation Cough Headache disorder Nausea |
Abdominal distension Abnormal hepatic function tests Back pain Chest pain Pain in extremities Vomiting |
| Rare/Very Rare |
|---|
|
Behavioral disorders |
The following precautions are available for L-GLUTAMINE (glutamine):
The safety and effectiveness of L-glutamine have been established in pediatric patients 5 years and older. Use of L-glutamine is supported by evidence from 2 placebo-controlled studies in adult and pediatric patients with sickle cell disease. The clinical studies enrolled 110 pediatric patients in the following age groups: 46 children (5 years up to less than 12 years) and 64 adolescents (12 years to less than 17 years). The safety and effectiveness of L-glutamine in pediatric patients with sickle cell disease younger than 5 years old has not been established.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no available data on L-glutamine use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Animal reproduction studies were not conducted with L-glutamine. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications.
The background risk of major birth defects and miscarriage for the indicated population are unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
The background risk of major birth defects and miscarriage for the indicated population are unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
There are no data on the presence of L-glutamine in human milk, the effect on the breastfed infant or the effect on milk production. The developmental and health benefits from breastfeeding should be considered along with the mother's clinical need for L-glutamine and any potential adverse effects on the breastfed child from L-glutamine or from the underlying maternal condition.
Clinical studies of L-glutamine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
The following prioritized warning is available for L-GLUTAMINE (glutamine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for L-GLUTAMINE (glutamine)'s list of indications:
| Sickle cell disease | |
| D57 | Sickle-cell disorders |
| D57.0 | Hb-SS disease with crisis |
| D57.00 | Hb-SS disease with crisis, unspecified |
| D57.01 | Hb-SS disease with acute chest syndrome |
| D57.02 | Hb-SS disease with splenic sequestration |
| D57.03 | Hb-SS disease with cerebral vascular involvement |
| D57.04 | Hb-SS disease with dactylitis |
| D57.09 | Hb-SS disease with crisis with other specified complication |
| D57.1 | Sickle-cell disease without crisis |
| D57.2 | Sickle-cell/hb-C disease |
| D57.20 | Sickle-cell/hb-C disease without crisis |
| D57.21 | Sickle-cell/hb-C disease with crisis |
| D57.211 | Sickle-cell/hb-C disease with acute chest syndrome |
| D57.212 | Sickle-cell/hb-C disease with splenic sequestration |
| D57.213 | Sickle-cell/hb-C disease with cerebral vascular involvement |
| D57.214 | Sickle-cell/hb-C disease with dactylitis |
| D57.218 | Sickle-cell/hb-C disease with crisis with other specified complication |
| D57.219 | Sickle-cell/hb-C disease with crisis, unspecified |
| D57.4 | Sickle-cell thalassemia |
| D57.40 | Sickle-cell thalassemia without crisis |
| D57.41 | Sickle-cell thalassemia, unspecified, with crisis |
| D57.411 | Sickle-cell thalassemia, unspecified, with acute chest syndrome |
| D57.412 | Sickle-cell thalassemia, unspecified, with splenic sequestration |
| D57.413 | Sickle-cell thalassemia, unspecified, with cerebral vascular involvement |
| D57.414 | Sickle-cell thalassemia, unspecified, with dactylitis |
| D57.418 | Sickle-cell thalassemia, unspecified, with crisis with other specified complication |
| D57.419 | Sickle-cell thalassemia, unspecified, with crisis |
| D57.42 | Sickle-cell thalassemia beta zero without crisis |
| D57.43 | Sickle-cell thalassemia beta zero with crisis |
| D57.431 | Sickle-cell thalassemia beta zero with acute chest syndrome |
| D57.432 | Sickle-cell thalassemia beta zero with splenic sequestration |
| D57.433 | Sickle-cell thalassemia beta zero with cerebral vascular involvement |
| D57.434 | Sickle-cell thalassemia beta zero with dactylitis |
| D57.438 | Sickle-cell thalassemia beta zero with crisis with other specified complication |
| D57.439 | Sickle-cell thalassemia beta zero with crisis, unspecified |
| D57.44 | Sickle-cell thalassemia beta plus without crisis |
| D57.45 | Sickle-cell thalassemia beta plus with crisis |
| D57.451 | Sickle-cell thalassemia beta plus with acute chest syndrome |
| D57.452 | Sickle-cell thalassemia beta plus with splenic sequestration |
| D57.453 | Sickle-cell thalassemia beta plus with cerebral vascular involvement |
| D57.454 | Sickle-cell thalassemia beta plus with dactylitis |
| D57.458 | Sickle-cell thalassemia beta plus with crisis with other specified complication |
| D57.459 | Sickle-cell thalassemia beta plus with crisis, unspecified |
| D57.8 | Other sickle-cell disorders |
| D57.80 | Other sickle-cell disorders without crisis |
| D57.81 | Other sickle-cell disorders with crisis |
| D57.811 | Other sickle-cell disorders with acute chest syndrome |
| D57.812 | Other sickle-cell disorders with splenic sequestration |
| D57.813 | Other sickle-cell disorders with cerebral vascular involvement |
| D57.814 | Other sickle-cell disorders with dactylitis |
| D57.818 | Other sickle-cell disorders with crisis with other specified complication |
| D57.819 | Other sickle-cell disorders with crisis, unspecified |
Formulary Reference Tool